Krystal Biotech Inc (KRYS)
Profitability ratios
Return on sales
| Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 4.28% | -72.07% | -927.91% | -11,334.12% | -10,340.17% | — | — | — | — | — | — | — | — | — | — | — | -1,369.37% | -577.96% | -425.93% | -342.11% |
| Operating profit margin | -66.11% | -193.95% | -1,576.45% | -18,923.73% | -17,774.78% | — | — | — | — | — | — | — | — | — | — | — | -4,304.80% | -1,962.67% | -1,408.20% | -1,056.44% |
| Pretax margin | 57.84% | 22.80% | -318.33% | -17,355.87% | -16,725.22% | — | — | — | — | — | — | — | — | — | — | — | -3,748.71% | -1,696.71% | -1,228.46% | -956.44% |
| Net profit margin | 55.92% | 19.32% | -318.33% | -17,355.87% | -16,725.22% | — | — | — | — | — | — | — | — | — | — | — | -3,748.71% | -1,696.71% | -1,228.46% | -956.44% |
Based on the profitability ratios provided for Krystal Biotech Inc, the company's performance has been highly variable over the past few quarters.
1. Gross Profit Margin: Krystal Biotech's gross profit margin has fluctuated significantly, ranging from -10,340.17% to 4.28%. This indicates that the company's cost of goods sold has at times exceeded its revenues by a substantial margin, leading to negative margins in some periods.
2. Operating Profit Margin: The operating profit margin has also shown extreme volatility, with figures as low as -18,923.73%. This suggests that the company's operating expenses relative to its revenue have been disproportionately high, resulting in significant operating losses.
3. Pretax Margin and Net Profit Margin: While the pretax margin and net profit margin have exhibited inconsistency, both ratios have shown periods of negative profitability, with figures as low as -17,355.87%. This indicates that, after accounting for all expenses and taxes, the company has incurred significant losses in certain quarters.
Overall, the profitability ratios demonstrate that Krystal Biotech Inc has experienced significant challenges in generating profits and controlling costs, leading to substantial losses in certain reporting periods. Investors and stakeholders should closely monitor the company's financial performance and strategies to address the underlying issues impacting profitability.
Return on investment
| Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | -7.92% | -13.41% | -18.68% | -22.38% | -27.04% | -26.00% | -22.95% | -19.37% | -16.88% | -10.90% | -12.60% | -11.46% | -9.35% | -10.62% | -9.23% | -7.67% | -11.37% | -10.56% | -8.82% | -7.80% |
| Return on assets (ROA) | 6.70% | 1.34% | -3.77% | -20.53% | -25.44% | -25.06% | -22.51% | -19.20% | -16.81% | -11.11% | -12.89% | -11.76% | -9.62% | -10.35% | -8.71% | -6.85% | -9.90% | -9.13% | -7.70% | -7.06% |
| Return on total capital | -8.46% | -14.09% | -19.53% | -23.44% | -29.37% | -27.80% | -24.47% | -20.83% | -18.99% | -11.50% | -13.92% | -12.15% | -9.61% | -11.30% | -9.52% | -7.88% | -11.76% | -10.88% | -9.10% | -8.07% |
| Return on equity (ROE) | 7.15% | 1.40% | -3.94% | -21.50% | -27.64% | -26.80% | -23.99% | -20.65% | -18.91% | -11.72% | -14.24% | -12.46% | -9.90% | -11.01% | -9.00% | -7.04% | -10.24% | -9.41% | -7.94% | -7.31% |
Based on the profitability ratios of Krystal Biotech Inc for various periods, we can observe the following trends:
1. Operating Return on Assets (Operating ROA):
- The Operating ROA shows a negative trend over the periods, indicating that the company is not generating sufficient operating income relative to its assets.
- The performance has worsened over time, with a decrease from -7.92% in March 2024 to -27.04% in March 2023.
2. Return on Assets (ROA):
- ROA also displays a negative trend, reflecting a decline in the company's ability to generate profits from its total assets.
- The ROA has shown substantial volatility, ranging from 6.70% in March 2024 to -25.44% in March 2023.
3. Return on Total Capital:
- The return on total capital exhibits a consistent negative trend, indicating inefficiencies in generating returns on the total invested capital.
- The performance has deteriorated over time, with the ratio decreasing from -8.46% in March 2024 to -29.37% in March 2023.
4. Return on Equity (ROE):
- ROE also shows a negative trend, reflecting a decreasing ability to generate profits for the shareholders' equity invested in the company.
- The ROE has experienced fluctuations, ranging from 7.15% in March 2024 to -27.64% in March 2023.
In summary, Krystal Biotech Inc's profitability ratios have generally been negative or declining, indicating challenges in efficiently utilizing assets, generating profits, and providing returns to shareholders. This trend suggests a need for the company to address operational inefficiencies and improve its overall financial performance.